Key words : dermatology, itch, pathogenesis, prurigo nodularis, TH2
Le texte complet de cet article est disponible en PDF.
| Funding sources: None.
| Conflicts of interest: Dr Yosipovitch has been a member of the scientific board of Menlo Therapeutics and a principal investigator in a Menlo-sponsored trial but was not involved in the current study. He is a consultant for and scientific advisory board member of Trevi, Sienna, Galderma, Sanofi Regeneron, Pfizer, Novartis, Dermavenda, Bayer, and Kiniksa and a principal investigator for Pfizer, Leo, Sun Pharma, Kiniksa, and Regeneron.
| Reprints not available from the author.